Invivyd publishes research comparing COVID antibody to vaccine side effects
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination
May 11, 2026 7:01 AM EDTInvivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for comparison to contemporary COVID-19 mRNA and protein vaccine tolerability, as well as epidemiologic extrapolation of systemic symptom days experienced via each approachUpcoming LIBERTY trial head-to-head study comparing safety and tolerability between VYD2311 and mRNA vaccine will build on these results in a rigorous, prospective fashion
NEW HAVEN, Conn., May 11, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that a preprint of original... More
